(Q46111102)

19 December 2017

title

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma (English)

1 reference

19 December 2017

1 reference

Joseph M Tuscano

1

1 reference

19 December 2017

Mrinal Dutia

2

1 reference

19 December 2017

Karen Chee

3

1 reference

19 December 2017

Ann Brunson

4

1 reference

19 December 2017

Christine Reed-Pease

5

1 reference

19 December 2017

Mehrdad Abedi

6

1 reference

19 December 2017

Jeanna Welborn

7

1 reference

19 December 2017

Robert T O'Donnell

8

1 reference

19 December 2017

language of work or name

English

0 references

publication date

7 March 2014

1 reference

19 December 2017

British Journal of Haematology

published in

1 reference

19 December 2017

volume

165

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

page(s)

375-381

1 reference

19 December 2017

The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy

cites work

1 reference

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

21 January 2018

1 reference

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.

21 January 2018

1 reference

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

21 January 2018

1 reference

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

21 January 2018

1 reference

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

21 January 2018

1 reference

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

21 January 2018

1 reference

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12755

1 reference

19 December 2017

1 reference

19 December 2017